p38<i>β</i> Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial <i>β</i>-Endorphin Expression.
Mol Pharmacol · 2017
Last updated 2026-05-28In lab tests, the GLP-1 drug exenatide increased microglial cells' production of a pain-relieving molecule called β-endorphin in a dose-dependent way, with effective concentrations of 4.1 and 7.5 nM. The drug worked by activating a specific signaling pathway involving proteins called PKA, p38, and CREB. Blocking this pathway prevented the increase in β-endorphin, and reducing p38 (but not p38) eliminated the effect in both cells and rats with nerve pain.
AI summary of the abstract below.
| Journal | Mol Pharmacol, 2017 |
|---|---|
| Citations | 34 |
| Relative citation ratio | 1.66 |
| NIH percentile | 68 |
| Molecules | exenatide |
| Conditions studied | Depression, Alzheimers |
Abstract
Recent discoveries established that activation of glucagon-like peptide-1 receptors (GLP-1Rs) mediates neuroprotection and antinociception through microglial -endorphin expression. This study aimed to explore the underlying signaling mechanisms of microglial -endorphin. GLP-1Rs and -endorphin were coexpressed in primary cultures of microglia. Treatment with the GLP-1R agonist exenatide concentration-dependently stimulated microglial expression of the -endorphin precursor gene proopiomelanocortin (POMC) and peptides, with EC values of 4.1 and 7.5 nM, respectively. Exenatide also significantly increased intracellular cAMP levels and expression of -protein kinase A (PKA), -p38, and -cAMP response element binding protein (CREB) in cultured primary microglia. Furthermore, exenatide-induced microglial expression of POMC was completely blocked by reagents that specifically inhibit adenylyl cyclase and activation of PKA, p38, and CREB. In addition, knockdown of p38 (but not p38) using short interfering RNA (siRNA) eliminated exenatide-induced microglial p38 phosphorylation and POMC expression. In contrast, lipopolysaccharide increased microglial activation of p38, and knockdown of p38 (but not p38) partially suppressed expression of proinflammatory factors (including tumor necrosis factor-, interleukin-1, and interleukin-6). Exenatide-induced phosphorylation of p38 and CREB was also totally blocked by the PKA inhibitor and siRNA/p38, but not by siRNA/p38 Seven-day intrathecal injections of siRNA/p38 (but not siRNA/p38) completely blocked exenatide-induced spinal p38 activation, -endorphin expression, and mechanical antiallodynia in rats with established neuropathy, although siRNA/p38 and siRNA/p38 were not antiallodynic. To our knowledge, our results are the first to show a causal relationship between the PKA-dependent p38 mitogen-activated protein kinase/CREB signal cascade and GLP-1R agonism-mediated microglial -endorphin expression. The differential role of p38 and p38 activation in inflammation and nociception was also highlighted.
Verbatim abstract via PubMed 28202578 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.